

Circulating extracellular vesicles as non-invasive biomarker of rejection in heart transplant

*Original*

Circulating extracellular vesicles as non-invasive biomarker of rejection in heart transplant / Castellani, Chiara; Burrello, Jacopo; Fedrigo, Marny; Burrello, Alessio; Bolis, Sara; Di Silvestre, Dario; Tona, Francesco; Bottio, Tomaso; Biemmi, Vanessa; Toscano, Giuseppe; Gerosa, Gino; Thiene, Gaetano; Basso, Cristina; Longnus, Sarah L; Vassalli, Giuseppe; Angelini, Annalisa; Barile, Lucio. - In: THE JOURNAL OF HEART AND LUNG TRANSPLANTATION. - ISSN 1053-2498. - 39:10(2020), pp. 1136-1148. [10.1016/j.healun.2020.06.011]

*Availability:*

This version is available at: 11583/2978530 since: 2023-05-16T11:54:22Z

*Publisher:*

ELSEVIER SCIENCE INC

*Published*

DOI:10.1016/j.healun.2020.06.011

*Terms of use:*

This article is made available under terms and conditions as specified in the corresponding bibliographic description in the repository

*Publisher copyright*

(Article begins on next page)

## **Circulating Extracellular Vesicles as a Noninvasive Biomarker of Rejection in Heart Transplant**

C. Castellani<sup>1\*</sup>, J. Burrello<sup>2\*</sup>, M. Fedrigo<sup>1</sup>, A. Burrello,<sup>3</sup> S. Bolis<sup>2</sup>,

D. Di Silvestre<sup>4</sup>, F. Tona<sup>5</sup>, T. Bottio<sup>5</sup>, V. Biemmi<sup>2,7</sup>, G. Toscano<sup>5</sup>, G. Gerosa<sup>5</sup>, G. Thiene<sup>1</sup>,

C. Basso<sup>1</sup>, S.L. Longnus<sup>6</sup>, G. Vassalli<sup>2,7</sup>, A. Angelini<sup>1#</sup>, L. Barile<sup>2,7,8#</sup>.

(1) Cardiovascular Pathology and Pathological Anatomy, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy. (2) Laboratory of Cellular and Molecular Cardiology and Laboratory for Cardiovascular Theranostics, Cardiocentro Ticino Foundation, Lugano, Switzerland. (3) Department of Electrical, Electronic and Information Engineering "Guglielmo Marconi" (DEI), University of Bologna, Italy. (4) Proteomics and Metabolomic Lab, ITB-CNR, Segrate, Italy. (5) Division of Cardiac Surgery, Dept. of Cardiac-Thoracic Vascular Sciences and Public Health, University of Padua, Italy. (6) Department of Cardiovascular Surgery, Inselspital, Bern University Hospital, Bern, Switzerland. (7) Faculty of Biomedical Sciences, Università Svizzera Italiana, Lugano, Switzerland. (8) Institute of Life Science, Scuola Superiore Sant'Anna, Pisa, Italy.

\*Equally contributing first authors. #Equally contributing last authors.

Manuscript word count: 6990 including references and figure captions. Abstract word count: 250

Number of Tables: 1; Number of Figures: 6.

Supplementary data: 11 Supplementary Tables and 2 Supplementary Figures.

Addresses for correspondence:

Annalisa Angelini (email: [annalisa.angelini@unipd.it](mailto:annalisa.angelini@unipd.it)) – Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova - Via A. Gabelli 61, 35121 – Padova (Italy)

Lucio Barile (email: [lucio.barile@cardiocentro.org](mailto:lucio.barile@cardiocentro.org)) – Laboratory for Cardiovascular Theranostics, Cardiocentro Ticino Foundation - Via Tesserete 48, 6900 – Lugano (Switzerland).

1 **ABSTRACT**

2 *Aims* – Circulating extracellular vesicles (EV) are raising considerable interest as a non-invasive  
3 diagnostic tool as they are easily detectable in biological fluids and contain specific set of nucleic acids,  
4 proteins, and lipids reflecting pathophysiological conditions. We aimed to investigate differences in  
5 plasma-derived EV surface-protein profile as biomarker to be used in combination with endomyocardial  
6 biopsies (EMB) for the diagnosis of allograft rejection.

7 *Methods and results* – Plasma was collected from 90 patients (53 training cohort, 37 validation cohort)  
8 prior to EMB. EV concentration was assessed by nanoparticle tracking analysis. EV surface antigens  
9 were measured using a multiplex flow cytometry assay comprising 37 fluorescently labelled capture bead  
10 populations coated with specific antibodies directed against respective EV surface epitopes. The  
11 concentration of EV was significantly increased and their diameter decreased in patients undergoing  
12 rejection as compared to negative ones. The trend was highly significant for both antibody-mediated  
13 rejection (AMR), and acute cellular rejection ( $P<0.001$ ). Among EV-surface markers, CD3, CD2, ROR1,  
14 SSEA-4, HLA-I, and CD41b were identified as discriminants between controls and ACR, whereas HLA-  
15 II, CD326, CD19, CD25, CD20, ROR1, SSEA-4, HLA-I, and CD41b discriminated controls from  
16 patients with AMR. ROC curves confirmed a reliable diagnostic performance for each single marker  
17 (AUC range 0.727-0.939). According to differential EV-marker expression, a diagnostic model was built  
18 and validated in an external cohort of patients. Our model was able to distinguish patients undergoing  
19 rejection from those without rejection. The accuracy at validation in an independent external cohort  
20 reached 86.5%. Its application for patient management has the potential to reduce the number of EMBs.  
21 Further studies in a higher number of patients are required to validate this approach for clinical purpose.  
22 *Conclusions* - Circulating EV are highly promising as new tool to characterize cardiac allograft rejection  
23 and to be complementary to EMB monitoring.

24 **NARRATIVE ABSTRACT** - Our study describes a method for detecting and characterising circulating  
25 extracellular vesicles (EV) as a minimally invasive, liquid biopsy for the diagnosis of cardiac allograft  
26 rejection, and as a complementary tool to EMB monitoring. EV obtained from peripheral blood were  
27 profiled to identify rejection and its types in cardiac transplant recipients. A standardized and rapid tool  
28 was established using a fluorescent bead-based multiplex assay. We built a diagnostic model based on  
29 machine learning algorithms to identify non-rejecting patients who potentially do not require EMBs. EV  
30 profiling could represent a tool for non-invasive monitoring of allograft rejection in cardiac transplant  
31 recipients.

32

33 **Keywords:** Extracellular Vesicles; Allograft Rejection; Heart Transplant; Biomarker; Machine  
34 Learning.

35

36 **ABBREVIATION LIST:** EMB, endomyocardial biopsy; ACR, acute cellular rejection; AMR,  
37 antibody-mediated rejection; EV, extracellular vesicles; NTA, nanoparticle tracking analysis; FC, flow  
38 cytometry; MFI, median fluorescence intensity; RF, random forest; DSA, donor-specific antibody.

39

40

## 41 **INTRODUCTION**

42 Allograft rejection remains a serious complication during and after the first post-transplant year(1, 2).  
43 More than 25% of patients have rejection episodes within one year and face the risk of developing  
44 consequent graft dysfunction with increased morbidity and mortality(3). Thus, early detection of cardiac  
45 allograft rejection is crucial to lower the risk of late morbidity and mortality. The current gold standard  
46 for diagnosis and grading of rejection is via endomyocardial biopsy (EMB). EMB is performed either to  
47 confirm clinical diagnosis of allograft rejection, or routinely in asymptomatic patients, as surveillance

48 monitoring for rejection(4, 5). EMB has also been used to evaluate efficacy of immunosuppression  
49 therapies in several clinical trials in which patients underwent more than 10 EMB during the first year  
50 after transplant(6, 7). This procedure still faces unresolved issues such as invasive risk, sampling error,  
51 and inter-reader variability(8-10). There is a long-standing effort toward the discovery of sensitive and  
52 noninvasive methods for the diagnosis of rejection that could be used in combination with tissue  
53 histology for reducing the frequency of biopsies(11). New, promising approaches are based on genomic  
54 screening, including microRNA(12, 13), and mRNA profiling(14). The non-invasive detection of  
55 circulating cell-free DNA (cfDNA)(15), or graft-derived cell-free DNA (GcfDNA)(16) were also  
56 proposed to diagnose acute cellular rejection (ACR), but not antibody-mediated rejection (AMR).  
57 Because nucleic acids and cell-free proteins are unstable in the circulation, a reliable quantification  
58 remains a critical problem.

59 Cells secrete extracellular vesicles (EV) that are composed of bioactive molecules mediating intercellular  
60 communication processes(17) and activating intracellular signalling pathways of target cells(18, 19). EV  
61 released into the circulation and body fluids display different RNA, protein, and lipid contents reflecting  
62 the homeostatic state and function of EV-producing cells. A change in the pathophysiological status of  
63 tissues and/or organs affects the composition of circulating EV, resulting in a specific molecular  
64 signature(20-22). This is of particular interest with regard to acute inflammatory processes, since EV  
65 have emerged as key regulators in immune responses(23-25). In this context, EV have great potential as  
66 diagnostic biomarkers in various diseases, including cardiovascular diseases(22) and might represent a  
67 valuable tool to support EMB in the diagnosis of different types of cardiac rejection. Given its limited  
68 invasiveness, the profiling of blood-derived EV represents an interesting diagnostic approach for  
69 monitoring early, post-transplant status and for therapeutic management of patients.

70 Here, we assessed, in a clinical setting, the potential of surface profiling of circulating EV for the  
71 diagnosis of acute cardiac allograft rejection, as companion biomarker to EMB monitoring. A multiplex

72 flow cytometric assay using antibody-coated capture beads was used to investigate differences in EV  
73 antigen expression in patients with an EMB diagnosis of ACR or AMR. Differentially expressed EV-  
74 surface antigens were combined in a single diagnostic model, based on machine learning algorithms,  
75 allowing for high accuracy discrimination between patients with and without graft rejection and among  
76 the different types of rejection. Finally, we validated our computational approach in an independent  
77 cohort of patients.

78

## 79 **METHODS**

80 A detailed description of patient data, EV isolation and characterization protocols, statistical analyses,  
81 and diagnostic modelling is provided in the Supplementary Appendix.

### 82 *Patient selection and blood handling*

83 Patients undergoing heart transplant were recruited at the Cardio-Surgery Center Gallucci (Dept. of  
84 Cardiac-Thoracic-Vascular Sciences and Public Health at the University Hospital of Padua, Italy). The  
85 study was approved by the local ethical committee and fully informed, written consent was provided by  
86 each patient. A total of 90 plasma samples were included and split into a training set (n=53) and a  
87 validation cohort (n=37). Patients with a first episode of rejection within 1 year since transplant were  
88 included in the study. Patients without rejection episodes within 1 year since transplant were enrolled as  
89 controls (Rejection 0, R0).

90 Patients from the training cohort were retrospectively selected between February 2018 and March 2019,  
91 including only subjects with an unequivocal diagnosis at EMB. According to the ISHLT classification  
92 for ACR, we selected EMBs showing 2R or 3A grade that correspond to multifocal inflammatory  
93 infiltrate, and multiple foci of myocyte necrosis. For AMR diagnosis, we selected EMBs corresponding  
94 to pAMR 1(I+) or pAMR 2, in presence of positivity for circulating donor specific antibodies.

95 For the validation cohort, we included 37 unselected consecutive patients, admitted for EBM between

96 April 2019 and January 2020, regardless of the final histologic diagnosis.

97 We excluded, from both validation and training cohorts, patients with other acute or chronic  
98 inflammatory disease (e.g., auto-immune disease, cancer, active infections).

99 All transplanted patients were ABO-compatible and were treated with cyclosporine, mycophenolate, and  
100 corticosteroids. All subjects enrolled in our study were scheduled for a surveillance biopsy in their regular  
101 follow-up after heart transplant in a setting of stable allograft function. Patients did not display any  
102 clinical signs/symptoms related to graft rejection (none of the patients was enrolled because rejection  
103 was suspected). Blood sampling was performed immediately before the EMB, thus avoiding potential  
104 confounding factors associated to procedure-related injury.

105 The diagnosis of either ACR or AMR was defined, according to the International Society for Heart and  
106 Lung Transplantation guidelines (4, 5) (see Supplementary Appendix).

107 Blood was collected in EDTA-treated tubes and centrifuged at 1,600 g for 15 minutes to separate plasma  
108 from cellular components; the low centrifuge speed avoided shear-stress-induced platelet activation.  
109 Plasma underwent serial centrifugation cycles to remove intact cells, cellular debris and larger EV:  
110 3,000 g for 20 minutes, 10,000 g for 15 minutes, and 20,000 g for 30 minutes (Figure 1A). Cleared,  
111 platelet-free plasma was finally stored at -80°C and not thawed prior to analysis.

112 Plasma-derived EV quantification

113 Presence of specific EV markers and absence of apolipoprotein contaminants were assessed by western  
114 blotting. Size and concentration of plasma EV were determined by nanoparticle tracking analysis (NTA)  
115 using NanoSight LM10 (*Malvern Instruments, UK*) equipped with a 405 nm laser and Nanoparticle  
116 Tracking Analysis NTA 2.3 analytic software. EV concentration is shown as EV/mL (median value,  
117 interquartile range).

118 EV surface marker analysis by multiplex flow cytometry

119 All samples underwent bead-based EV immunocapture and were analyzed by flow cytometry (FC),

120 using MACSPlex human Exosome Kit (*Miltenyi Biotec, Germany*), according to manufacturer's  
121 instructions. Median fluorescence intensity (MFI) was measured on a MACSQuant Analyzer 10 flow  
122 cytometer according to previous validation studies(26-29). The multiplex platform analysis and  
123 gating strategy have previously been described(26, 28). MFI was evaluated for each subset of capture  
124 beads, corrected by subtracting the MFI of corresponding blank controls, and normalized by the mean  
125 MFI of CD9, CD63, and CD81.

### 126 Statistical analysis and diagnostic modelling

127 IBM SPSS Statistics 22 (IBM Corp., Armonk, New York, USA) and GraphPad PRISM 7.0a (La Jolla,  
128 California, USA) were used for statistical analyses. Scalar variables were analyzed with Kolmogorov–  
129 Smirnov test to evaluate distributions. Normally distributed variables are expressed as mean  $\pm$  standard  
130 deviation and were analyzed by ANOVA with post-hoc Bonferroni's tests; non-normally distributed  
131 variables are expressed as median [interquartile range] and were analyzed by Kruskal-Wallis tests.  
132 Categorical variables are expressed as absolute number (percentage) and were compared with chi-square  
133 tests (Fisher's exact test when sample size was  $\leq 5$ ). Correlations were evaluated by Pearson's test (R  
134 coefficient) and analysis of regression curves. Receiver operating characteristics (ROC) curves were used  
135 to assess the area under the curve (AUC) and to compare diagnostic performances of selected variables;  
136 the Younden Index ( $J = \text{sensitivity} + \text{specificity} - 1$ ) was calculated to assess the best sensitivity and  
137 specificity. *P*-values of less than 0.05 were considered significant.

138 Machine learning supervised algorithms are exploited in clinical practice to formulate predictions of  
139 selected outcomes based on a given set of labeled, paired, input-output training sample data(30, 31). To  
140 build the diagnostic model, a random forest (RF) algorithm was created using Python 3.5 (library, scikit-  
141 learn). The algorithm created 40 different classification trees; if at least 21 of 40 trees of the RF indicate  
142 the absence of rejection, the patient was classified as R0 (level 1); in case of detection of graft rejection,  
143 a second RF algorithm was created to distinguish ACR from AMR (level 2). A combined model was also



144 built to distinguish R0 vs. ACR vs. AMR, in a single step. Models were both internally and externally  
145 validated. Internal validation was provided by a leave-one-out cross-validation algorithm (see  
146 Supplementary Appendix). External validation was performed on an independent cohort enrolled in the  
147 same center.

#### 148 Protein interactor network analysis

149 Protein interactors of the EV-surface marker were retrieved by Cytoscape PESCA plugin(32) and a  
150 global *Homo sapiens* protein-protein interaction (PPI) network of 1588 nodes and 36984 edges was  
151 reconstructed. For each quantitative comparison (R0 vs. ACR and R0 vs. AMR), a specific PPI sub-  
152 network per comparison was reconstructed considering the first neighbors of each differentially  
153 expressed EV-surface marker protein.

154

## 155 **RESULTS**

#### 156 Patient characteristics

157 We enrolled 90 subjects, 53 in the training cohort and 37 in the validation cohort. Patient characteristics  
158 are summarized in Tables 1, S1, and S2. All subjects enrolled were scheduled for a surveillance biopsy  
159 in their regular follow-up in a setting of stable allograft function.

160 According to EMB parameters and biochemical analyses, patients from training cohort were divided in  
161 three groups (R0, ACR, AMR). They were similar with respect to sex and age, whereas the time from  
162 heart transplant to rejection was 3 [2;8] months for the ACR group compared to 11 [9;14] months for the  
163 AMR group ( $P=0.004$ ). Among AMR patients, 4 of 9 (44.4%) presented with capillary deposition of  
164 complement fraction C4d, and 2 of 9 (22.2%), with CD68-positive staining in macrophages with a  
165 grading >10%. The anti-HLA antibody assessment revealed all AMR patients as positive for anti-HLA-  
166 II donor-specific antibodies (DSA) and anti-HLAII non-DSA. Moreover, 8 of 9 (88.9%) patients in the  
167 AMR group displayed a strong positivity for anti-HLA-I non-DSA. As expected, the cellular rejection

168 score was higher in patients with ACR compared to both controls and AMR patients. Biochemical  
169 parameters and the ejection fraction at echocardiography are reported in Table S2. For diagnostic  
170 modelling purpose, an independent cohort was enrolled. Clinical, biochemical, and EMB parameters did  
171 not significantly differ from the training cohort (Table S3).

### 172 EV quantification

173 The immunocapture assay was validated for its specificity to bind vesicles by western blotting analysis  
174 for the presence of specific EV markers such as TSG101 and CD81 and for the absence of contaminants  
175 such as apolipoprotein (ApoB48; Figure 1B). Given the reliability of the immunocapture protocol, we  
176 used the level of expression of tetraspanins CD9, CD63, and CD81 (generally accepted EV surface  
177 markers) for specific quantification of circulating EV. The MFI of tetraspanins was higher in patients  
178 with ACR and AMR, compared to R0 ( $P<0.001$ ; Figure 1C and Table S4).

179 Size and concentration profiles of circulating EV were determined by NTA. NTA confirmed a significant  
180 increase of the concentration of plasma-derived EV in patients undergoing rejection compared to subjects  
181 classified as R0; no differences were observed between ACR and AMR (Figure S1A and Table S4).

182 Overall, the increase in the total number of EV reflects a concentration of the smaller subset (30-150 nm)  
183 that was approximately three-fold higher in ACR and AMR compared to R0 ( $P<0.01$  for both  
184 comparisons; Figure S1A). Consistently, the median EV diameter was significantly lower in ACR and  
185 AMR vs. R0 ( $P<0.001$ ; Figure S1B and Table S4). Cumulative distribution plots (EV concentration vs.  
186 particle size), resulted in a left-shift of curves and higher AUC for ACR and AMR as compared to R0  
187 ( $P<0.001$  for both; Figure 1D). Although NTA cannot distinguish EV from other particles such as  
188 lipoproteins, the analysis correlates with the antigenic quantification of CD9/CD63/CD81 (Pearson's  
189  $R=0.463$ ;  $P<0.001$ ; Figure 1E).

### 190 Analysis of EV-surface markers

191 Immunocaptured EV from pre-cleared plasma of patients from the training cohort (n=53) were analyzed  
192 for the expression of 37 different surface antigens (Table S5). Several biomarkers were significantly  
193 higher in both ACR and AMR patients compared to R0 (Figure 2A). This applied for four antigens  
194 including the molecules of major histocompatibility complex class-I (HLA-I), the platelet membrane  
195 glycoprotein II-b (CD41b) and two non-immune system-related antigens: tyrosine-protein kinase  
196 transmembrane receptor (ROR1) and Stage-Specific Embryonic Antigen-4 (SSEA-4). Expression levels  
197 of two T-cell surface antigens, CD2 and CD3, that function as a cell adhesion molecule and a co-receptor  
198 activator, respectively, were differentially expressed between ACR patients vs. R0. In addition, the  
199 surface EV expression of five, well-established, immunologic markers was significantly higher in AMR  
200 patients as compared to R0: major histocompatibility complex class II (HLA-II), the epithelial cell  
201 adhesion molecule (CD326), B-lymphocyte antigens CD19 and CD20 and the interleukin-2 receptor  
202 alpha chain (CD25). Compared to R0, the heatmap highlights clusters corresponding to high MFI for  
203 CD2, CD3, ROR1, SSEA-4, HLA-I and CD41b in ACR patients, and to high ROR1, SSEA-4, HLA-I,  
204 CD41b, HLA-II, CD326, CD19, CD25, and CD20 in AMR patients (Figure 2B).

### 205 Diagnostic Modelling

206 The power of discrimination between patients presenting graft rejection and non-rejecting R0 controls  
207 was evaluated by analysis of ROC curves for each single, differentially expressed EV-surface marker.  
208 Overall, the MFI analysis displayed a reliable diagnostic performance for all the evaluated markers  
209 (Figure 3). Comparing ACR vs. R0, the best performance was obtained for HLA-I (AUC 0.939), CD3  
210 (AUC 0.848) and SSEA-4 (AUC 0.832), CD2 (AUC 0.829). Of note, the MFI for EV-carried HLA-I,  
211 CD2 and SSEA-4 displayed a sensitivity of 100% in the diagnosis of ACR, with specificities ranging  
212 between 63.6 and 87.9% (Figure 3A, and 3C). For AMR vs. R0, ROR1 showed the best performance  
213 with an AUC of 0.879 (sensitivity and specificity of 100% and 75.8%, respectively), followed by HLA-  
214 I (AUC 0.872), SSEA-4 (AUC 0.820), CD20 (AUC 0.798), CD19 (AUC 0.795), HLA-II (AUC 0.788),

215 and CD41b (AUC 0.778). Strengthening our results, ROR1, SSEA-4, HLA-II and CD41b each achieved  
216 100% sensitivity, correctly identifying all patients with AMR (Figure 3B, and 3D).

217 After having demonstrated excellent diagnostic performances for each candidate biomarker considered  
218 individually, we combined the 11 differentially expressed EV-surface antigens in a single diagnostic  
219 model using machine learning algorithms. A RF classification model was used as computational  
220 approach to identify patients with heart rejection using the MFI of circulating EV-carried antigens  
221 (Figure 4). The RF model was developed in the training cohort (n=53) and then internally validated by a  
222 leave-one-out cross-validation algorithm (see methods), which simulated how the model could generalize  
223 on an independent cohort. Finally, we performed a real external validation of the RF model on an  
224 independent cohort enrolled in the same center.

225 At the training, a double level RF model was built as a first approach: the first level discriminated the  
226 presence of rejection (including both ACR and AMR) *vs.* no-rejection (R0) with an accuracy of 100%.

227 All identified rejecting subjects (n=20), were then introduced in the second level, to distinguish between  
228 the two rejection types (ACR *vs.* AMR); this second model also provided a very high performance with  
229 an accuracy of 95%. All patients except one were correctly identified; a single patient with AMR was  
230 classified as ACR (Figure 4A). Next, we built a combined model to classify patients in one single step  
231 (R0 *vs.* ACR *vs.* AMR); all subjects were correctly allocated with an accuracy of 100% (Figure 4B). We  
232 then provided an internal validation by a leave-one-out cross-validation algorithm to simulate how the  
233 algorithms could perform in an independent cohort and to exclude overfitting bias (effect due to the best  
234 performance of the model in the cohort in which it is trained). The accuracy was still very high (83% to  
235 88.7%), with a modest overfitting effect (11.3% to 17%). Finally, we tested our model in an independent  
236 external validation cohort (Figure 5). Consistently with the internal validation, the accuracy was 86.5%,  
237 81.3%, and 78.4%, respectively for level 1, level 2, and combined RF models, thus confirming a reliable  
238 diagnostic performance even in an external cohort of patients.

239 The enrollment of consecutive unselected patients in the validation cohort, allowed us to simulate a  
240 clinical context in which EV profiling and random forest model were integrated not to avoid EMBs, but  
241 to select patients for this procedure. With this approach, we would have correctly managed 34 of 37  
242 patients (accuracy 91.9%), while reducing by 56.8% the number of EMBs required (Figure 6).  
243 Unfortunately, 3 rejecting patients would have been predicted as R0, thus missing the possibility to be  
244 correctly managed by EMBs.

#### 245 Correlation analyses

246 Patients from training and validation cohorts were pooled and correlation analyses were performed to  
247 evaluate whether expression levels of EV-surface markers and EV concentration might relate to EMB  
248 findings and/or patient characteristics. Cellular rejection score correlates with EV concentration and with  
249 the expression level of SSEA-4, HLA-I, CD41b (R range 0.323-0.581,  $P<0.01$ ) in patients with ACR.  
250 Significant correlations have been also found between circulating levels of anti-HLA-I (DSA and non-  
251 DSA), and anti-HLA-II (DSA and non-DSA) antibodies and EV concentration, or MFI of ROR1 and  
252 HLA-I (R range 0.253-0.465,  $P<0.05$ ; Table S6) in patients with AMR.

253 Moreover, a significant correlation was found between lymphocyte counts and EV concentration. The  
254 number of lymphocytes and/or monocytes were also correlated to expression levels of HLA-II, CD25,  
255 HLA-I, SSEA-4, and CD41b in AMR and R0 patients, and to the expression of CD2, SSEA-4, and  
256 CD41b in ACR and R0 patients (Table S7). No significant correlations were observed between EV-  
257 surface markers and age at heart transplant, or time to rejection onset.

258 A sub-analysis aiming to assess the sex-specific expression of EV surface antigens demonstrated a  
259 selective over-expression of CD3, CD19, CD2, CD25, and CD20 in rejecting females, whereas CD41b  
260 was over-expressed in male rejecting patients. In addition, the increase in EV concentration assessed by  
261 CD9/CD63/CD81 MFI was more relevant in female patients with rejection, as compared to males (Table  
262 S8). Finally, we performed a correlation analysis between EMB findings and the expression of EV

263 markers. CD3, ROR1, SSEA-4, HLA-I, and CD41b MFI were directly correlated to the presence of  
264 inflammatory infiltrate, myocytolysis, myocyte necrosis, and/or vasculitis in ACR patients (R range  
265 0.239-0.513,  $P<0.05$ ). HLA-II, SSEA-4, and HLA-I were correlated to the presence of inflammatory  
266 infiltrate and vasculitis in AMR patients (R range 0.238-0.462,  $P<0.05$ ; Table S9).

### 267 Protein interactor network analysis

268 Since secreted EV have been shown to mediate autocrine, paracrine and endocrine signaling, we  
269 performed a theoretical analysis to predict possible protein-protein interactors. The network analysis  
270 allowed identification of potential protein targets, biological pathways and molecular functions that could  
271 be affected by EV-surface markers that were differentially expressed in rejecting vs. not rejecting  
272 patients. “Hubs” and “bottlenecks” refer to proteins with greater numbers of protein connections or to  
273 those occupying critical network positions, suggesting pivotal roles for the management of information  
274 flow over the network (33) (Figure S1);. Except for HLA-E, hubs and bottlenecks in the interactor  
275 networks for ACR and AMR were different: ABI1, CD247, ERBB3, JUN, and B2M were identified as  
276 main interactors in ACR, whereas CD74, VAPA, SSR4, COPB1, PTCH1, DYNLL1, SGTA, RANBP9,  
277 and ITGA6 were main interactors in AMR (Tables S10, and S11). The higher number of EV-marker  
278 interactors in both ACR and AMR networks led to the enrichment of specific pathways related to the  
279 immune system and signal transduction, involving the inflammatory response, intercellular  
280 communication, cell survival, and apoptosis.

281

## 282 **DISCUSSION**

283 The present study highlights the diagnostic potential of circulating EV as biomarkers for monitoring  
284 cardiac allograft rejection. We found that the total amount of circulating vesicles assessed by the  
285 expression of specific surface antigens CD63, CD81, and CD9, discriminated between patients with and  
286 without rejection. Both ACR and AMR patients showed an increase in EV concentration, compared to

287 R0. Nanoparticle tracking analysis (NTA), which strongly correlated with the expression of tetraspanins  
288 (CD63, CD9 and CD81), showed an increase in EV concentration for rejecting patients, specifically for  
289 small-sized EVs ( $\leq 150$  nm, the size specifically associated with exosomes). These results are consistent  
290 with the notion that the inflammatory state induces the release of microvesicles (34). Most importantly,  
291 plasma-derived EV carry a specific set of surface antigens, reflecting the change in immunologic profile  
292 of heart transplant recipients. The level of expression of specific, membrane-associated markers  
293 significantly diverged in patients with no rejection from those with rejection, and above all, different  
294 types of rejection were discriminated by EV profiling. Eleven of 37 analyzed surface antigens were  
295 differentially expressed in patients with ACR and AMR compared to patients without rejection. Six  
296 markers identified a cluster of patients with ACR, whereas nine markers identified patients with AMR.  
297 Finally, ROC curves revealed high performances for the evaluated EV markers, with 100% sensitivity  
298 reached for several markers (HLA-I, CD2 and SSEA-4 for ACR; ROR1, SSEA-4, HLA-II and CD41b  
299 for AMR). The diagnostic potential was further improved by combining MFI values of the 11 EV surface  
300 antigens differentially expressed between groups through a machine learning approach.

301 The accuracy of our computational approach resulted in a theoretical validation of  $\sim 89\%$  and it stands at  
302  $\sim 87\%$  when the validation was performed on a separate cohort of patients, with a negligible overfitting  
303 effect of about 2%.

304 In light of what stated above, the immuno-profiling of plasma-derived EV and the integration of complex  
305 computational approaches in the management of patients after heart transplant, would help clinicians to  
306 discriminate between patients requiring EMB from those who may not require this procedure.

307 The major strength of EV profiling approach is that it resulted in a consistent (it has been validated on  
308 patients) and reliable (with a relevant diagnostic performance) non-invasive diagnostic test, that can  
309 eventually reduce the number of biopsies for non-rejecting patients. By using the proposed model to  
310 simulate the management of subjects included in the validation cohort (37 consecutively enrolled

311 patients), introducing blood sampling and EV analysis before the EMB procedure, we could have reduced  
312 the number of patients selected for biopsy by 56.8% (flowchart in Figure 6). Unfortunately, three  
313 rejecting patients would have missed the possibility to be correctly managed through EMB.

314 Another strength that should be considered in envisioning the profiling of EV as potential diagnostic  
315 tool lies in the fact that by analyzing systemic circulating particles, clinicians can quickly grasp a more  
316 complete picture of patient's status. Indeed, differentially expressed markers on the surface of EV in  
317 blood may be more representative as compared to markers detected in tissue sample, which can be  
318 distorted by necrosis and fibrotic areas. Although, we did not select cardiac specific EV, as to date there  
319 is no specific antibody recognizing tissue specific vesicles, EV in blood presumably includes particles  
320 released from injured areas of tissue, but preferentially exclude necrotic areas in which circulation has  
321 ceased.

322 Other studies have evaluated profiling of circulating EV to non-invasively monitor cardiac allografts for  
323 rejection. Kennel et al. performed proteomic analysis by liquid chromatography-tandem mass  
324 spectrometry on serum-derived exosomes (small EV) collected from heart transplant recipients with no  
325 rejection, ACR, and AMR(35). They found that allograft rejection alters the protein content of circulating  
326 exosomes, giving them unique protein expression patterns, which are suitable as predictive and  
327 prognostic biomarkers. Although very interesting, the approach used by Kennel et al. was based on  
328 relatively complex methodologies and instrumentation. Here we propose the profiling of the surface of  
329 EV which does not require lysis or digestion steps and can be performed using conventional flow  
330 cytometers. Habbertheuer et al. have recently shown that transplanted hearts release donor-specific  
331 exosomes. In a murine model of heterotopic heart transplant, they elegantly showed that the cardiac  
332 allograft releases a distinct pool of donor MHC-specific exosomes into recipient circulation. The signal  
333 peaked during early stages of acute rejection with high accuracy(36) enabling the development of a very  
334 specific and sensitive biomarker platform for allograft monitoring (36, 37). Compared to this study that



335 was carried out in a model of major histocompatibility mismatch using immunodeficient recipient mice,  
336 our platform has been analyzed in a clinical setting, including immunocompetent recipients on  
337 maintenance immuno-suppression, and provides comparable accuracy.

338 Quantitative changes in microRNA cargo of serum exosomes from heart transplant recipients has also  
339 been demonstrated. Dewi and colleagues showed that microRNA miR-142-3p increased in case of  
340 ACR(38). miR-142-3p is enclosed into secreted exosomes from T cells and targets specific messenger  
341 RNA in endothelial cells, thus implying a role for T cell-derived EV in mediating graft rejection<sup>(38)</sup>. In  
342 line with this hypothesis, we found that CD3 and CD2, T cell co-receptors, were both upregulated on the  
343 surface of EV in patients with a diagnosis of ACR. It might be interesting, in the future, to assess whether  
344 the EV expressing these surface co-receptors also carry miR-142-3p. This scenario would reinforce the  
345 role of the endothelial-T cells axis in cell-mediated rejection.

346 EV surface antigens may also reflect activation of B-cells. The receptor tyrosine kinase ROR1, which is  
347 a transmembrane protein highly expressed on the surface of leukemia cells, but not on normal B-  
348 cells(39)(40), was significantly overexpressed in both AMR and ACR patients as compared to controls.  
349 However, none of the patients with rejection displayed proliferative hematologic disorders, thus ROR1  
350 expression on EV might reflect an activation state of B-cells, which is not associated with a malignant  
351 phenotype. Given the correlation with clinical, biochemical, and EMB parameters we found significantly  
352 correlated between EV-surface markers and the numbers of circulating lymphocytes and monocytes in  
353 rejecting patients. The total number of WBCs was not increased in patients with a diagnosis of rejection,  
354 suggesting that EV number and profile may reflect the activation state of these cells and the systemic  
355 inflammatory response in transplant rejection(41). EV surface markers were also correlated with the  
356 presence of inflammatory infiltrate, myocytolysis, myocyte necrosis, and vasculitis on EMB, being  
357 associated not only to the diagnosis of ACR/AMR, but also to the severity of the inflammatory response  
358 triggered by rejection.

359 Although beyond the scope of the present paper, we hypothesized that EV antigens may exert active  
360 biological functions providing autocrine and paracrine signals to target cells (19, 42)(43). In this regard,  
361 we performed a theoretical interactor network analysis which suggested that the large majority of proteins  
362 up-regulated on EV of rejecting patients may have a potential role as ligand–receptor interactors for  
363 several intercellular pathways involved in the inflammatory response to graft rejection. For instance,  
364 circulating EV can act as extracellular stimuli for Jun (hub/bottleneck in ACR network), which controls  
365 a number of cellular processes including differentiation, proliferation, and apoptosis through the  
366 formation of heterodimer AP-1(44). This carries importance when considering that allograft treatment  
367 with decoy oligodeoxynucleotides (ODN) targeting the transcription factor AP-1 delays acute rejection  
368 and prolongs cardiac allograft survival in a rat transplant model(45). Interestingly, the network analysis  
369 highlighted a possible EV-mediated induction of genes related to natural killer (NK) cells and these  
370 findings are in line with recent tissue-based gene profiling unveiling the association of NK transcripts  
371 with chronic allograft vasculopathy in AMR (46).

372 After stratification for sex, we found several EV markers selectively enriched in female rejecting patients.  
373 In particular, the overexpression of surface antigens CD19 and CD 20 (both markers of B-cells) is  
374 noteworthy, as it is known that estrogens amplify immuno-responses in women (47, 48). They act by  
375 increasing total number of progenitor B cells (49), and inducing B cell activation (50).

376 The main limit of the present study is that the patients used for training and validation of the model did  
377 not allow us for longitudinal-based cohort study, thus limiting the evaluation of our model as predictive  
378 approach. Indeed, a longitudinal cohort would have allowed the demonstration of whether this approach  
379 may identify rejection before the diagnosis made by EMB, and whether changes in EV related parameters  
380 may even anticipate the histologic evidence of rejection, thus enabling the institution of an earlier and  
381 perhaps less intrusive treatment. A second important issue is the absence of specific, cardiac-derived  
382 antigens among the EV markers included in the analysis, thus excluding the possibility of grading the

383 vascular damage and cardiac damage related to rejection. Another potential limitation is the relatively  
384 small sample size. Our selection strategy at training was based on a well-defined histological pattern at  
385 EMB (see methods). This allowed us to evaluate highly selected patients and train the diagnostic model  
386 on subjects that truly underwent rejection. On the other hand, this can be a limitation as the training of  
387 the model does not include subjects with mild forms of rejection. However, the validation of the model  
388 was performed on an unselected cohort of patients, thus suggesting a potential clinical application, even  
389 if the present findings still have to be confirmed in larger prospective cohorts. Finally, we showed that  
390 different types of rejection are associated with different EV phenotypes, but we cannot define whether  
391 these phenotypes are specific for rejection, as the large majority of antigens might be theoretical  
392 associated with other acute and chronic inflammatory diseases.

393 In conclusion, given its low cost, speed, and simplicity, as well as its high accuracy, the method here  
394 described provides a connection between allograft phenotypes, biochemical indexes, and histology  
395 parameters for the detection of different types of heart allograft rejection. Circulating plasma-derived EV  
396 are a highly promising tool for characterising and monitoring cardiac allograft rejection. It does not  
397 stand alone as diagnostic biomarker that could completely replace EMB. The quantitative flow cytometer  
398 analysis and the computational approach proposed here can act in synergy with tissue histology and offer  
399 a tool to clinician for reducing the number of biopsies and selecting patients with the highest risk of  
400 rejection for a closer follow-up.

401 **ACKNOWLEDGMENTS** - All authors contributed extensively to the work presented in this  
402 manuscript. L.B., and A.A. designed the study. C.C., F.T., T.B., G.G., and M.F. recruited patients and  
403 collected clinical information and blood samples. J.B., C.C., V.B., and S.B., performed the EV isolation  
404 and characterization. J.B., A.B., and D.D.S. performed statistics, diagnostic modelling, and protein  
405 interactor network analysis. J.B., C.C., A.A., and L.B. wrote the manuscript with inputs from all authors.  
406 S.L.L., G.T., C.B., G.V., L.B., and A.A. interpreted data and critically revised the manuscript.

407

408 **Source(s) of Funding:** This study was supported by research grant from University of Padua  
409 BIRD170215, BIRD199570 and by the Registry of Cardio-Cerebral-Vascular Pathology, Veneto Region,  
410 Italy. L.B. and S.L. were supported by research grant of Swiss National Science Foundation  
411 (IZCOZ0\_182948/1), Switzerland. L.B. was supported by research grant of Velux Stiftung, Zurich  
412 (Switzerland). This article is based upon work from COST Action EU-CARDIOPROTECTION  
413 CA16225 supported by COST (European Cooperation in Science and Technology).

414

415 **Conflict(s) of Interest/Disclosure(s):** nothing to disclose.

416 **REFERENCES**

- 417 1. Yusen RD, Edwards LB, Dipchand AI, et al.: The Registry of the International Society for Heart and  
418 Lung Transplantation: Thirty-third Adult Lung and Heart-Lung Transplant Report-2016; Focus  
419 Theme: Primary Diagnostic Indications for Transplant. *J Heart Lung Transplant* 2016;35:1170-84.
- 420 2. Weber BN, Kobashigawa JA, Givertz MM: Evolving Areas in Heart Transplantation. *JACC Heart*  
421 *Fail* 2017;5:869-78.
- 422 3. Lund LH, Edwards LB, Kucheryavaya AY, et al.: The registry of the International Society for Heart  
423 and Lung Transplantation: thirty-first official adult heart transplant report--2014; focus theme:  
424 retransplantation. *J Heart Lung Transplant* 2014;33:996-1008.
- 425 4. Stewart S, Winters GL, Fishbein MC, et al.: Revision of the 1990 working formulation for the  
426 standardization of nomenclature in the diagnosis of heart rejection. *J Heart Lung Transplant*  
427 2005;24:1710-20.
- 428 5. Berry GJ, Burke MM, Andersen C, et al.: The 2013 International Society for Heart and Lung  
429 Transplantation Working Formulation for the standardization of nomenclature in the pathologic  
430 diagnosis of antibody-mediated rejection in heart transplantation. *J Heart Lung Transplant*  
431 2013;32:1147-62.
- 432 6. Hershberger RE, Starling RC, Eisen HJ, et al.: Daclizumab to prevent rejection after cardiac  
433 transplantation. *N Engl J Med* 2005;352:2705-13.
- 434 7. Grimm M, Rinaldi M, Yonan NA, et al.: Superior prevention of acute rejection by tacrolimus vs.  
435 cyclosporine in heart transplant recipients--a large European trial. *Am J Transplant* 2006;6:1387-97.
- 436 8. Wong RC, Abrahams Z, Hanna M, et al.: Tricuspid regurgitation after cardiac transplantation: an  
437 old problem revisited. *J Heart Lung Transplant* 2008;27:247-52.
- 438 9. Nguyen V, Cantarovich M, Cecere R, Giannetti N: Tricuspid regurgitation after cardiac  
439 transplantation: how many biopsies are too many? *J Heart Lung Transplant* 2005;24:S227-31.

- 440 10. Bishawi M, Zanotti G, Shaw L, et al.: Tricuspid Valve Regurgitation Immediately After Heart  
441 Transplant and Long-Term Outcomes. *Ann Thorac Surg* 2019;107:1348-55.
- 442 11. Hamour IM, Burke MM, Bell AD, Panicker MG, Banerjee R, Banner NR: Limited utility of  
443 endomyocardial biopsy in the first year after heart transplantation. *Transplantation* 2008;85:969-74.
- 444 12. Di Francesco A, Fedrigo M, Santovito D, et al.: MicroRNA signatures in cardiac biopsies and  
445 detection of allograft rejection. *J Heart Lung Transplant* 2018;37:1329-40.
- 446 13. Duong Van Huyen JP, Tible M, Gay A, et al.: MicroRNAs as non-invasive biomarkers of heart  
447 transplant rejection. *Eur Heart J* 2014;35:3194-202.
- 448 14. Halloran PF, Potena L, Van Huyen JD, et al.: Building a tissue-based molecular diagnostic system  
449 in heart transplant rejection: The heart Molecular Microscope Diagnostic (MMDx) System. *J Heart  
450 Lung Transplant* 2017;36:1192-200.
- 451 15. De Vlaminck I, Valantine HA, Snyder TM, et al.: Circulating cell-free DNA enables noninvasive  
452 diagnosis of heart transplant rejection. *Sci Transl Med* 2014;6:241ra77.
- 453 16. Beck J, Oellerich M, Schulz U, et al.: Donor-Derived Cell-Free DNA Is a Novel Universal  
454 Biomarker for Allograft Rejection in Solid Organ Transplantation. *Transplant Proc* 2015;47:2400-  
455 3.
- 456 17. Maas SLN, Breakefield XO, Weaver AM: Extracellular Vesicles: Unique Intercellular Delivery  
457 Vehicles. *Trends Cell Biol* 2017;27:172-88.
- 458 18. S ELA, Mager I, Breakefield XO, Wood MJ: Extracellular vesicles: biology and emerging  
459 therapeutic opportunities. *Nat Rev Drug Discov* 2013;12:347-57.
- 460 19. Cervio E, Barile L, Moccetti T, Vassalli G: Exosomes for Intramyocardial Intercellular  
461 Communication. *Stem Cells Int* 2015;2015:482171.

- 462 20. Pant S, Hilton H, Burczynski ME: The multifaceted exosome: biogenesis, role in normal and  
463 aberrant cellular function, and frontiers for pharmacological and biomarker opportunities. *Biochem*  
464 *Pharmacol* 2012;83:1484-94.
- 465 21. Revenfeld AL, Baek R, Nielsen MH, Stensballe A, Varming K, Jorgensen M: Diagnostic and  
466 prognostic potential of extracellular vesicles in peripheral blood. *Clin Ther* 2014;36:830-46.
- 467 22. Barile L, Vassalli G: Exosomes: Therapy delivery tools and biomarkers of diseases. *Pharmacology*  
468 *& therapeutics* 2017;174:63-78.
- 469 23. Boulanger CM, Loyer X, Rautou PE, Amabile N: Extracellular vesicles in coronary artery disease.  
470 *Nat Rev Cardiol* 2017;14:259-72.
- 471 24. Haller PM, Stojkovic S, Piackova E, et al.: The association of P2Y12 inhibitors with pro-coagulatory  
472 extracellular vesicles and microRNAs in stable coronary artery disease. *Platelets* 2019:1-8.
- 473 25. Sarkar A, Mitra S, Mehta S, Raices R, Wewers MD: Monocyte derived microvesicles deliver a cell  
474 death message via encapsulated caspase-1. *PLoS One* 2009;4:e7140.
- 475 26. Wiklander OPB, Bostancioglu RB, Welsh JA, et al.: Systematic Methodological Evaluation of a  
476 Multiplex Bead-Based Flow Cytometry Assay for Detection of Extracellular Vesicle Surface  
477 Signatures. *Front Immunol* 2018;9:1326.
- 478 27. El Andaloussi S, Lakhil S, Mager I, Wood MJ: Exosomes for targeted siRNA delivery across  
479 biological barriers. *Adv Drug Deliv Rev* 2013;65:391-7.
- 480 28. Koliha N, Wiencek Y, Heider U, et al.: A novel multiplex bead-based platform highlights the  
481 diversity of extracellular vesicles. *J Extracell Vesicles* 2016;5:29975.
- 482 29. Andriolo G, Provasi E, Lo Cicero V, et al.: Exosomes From Human Cardiac Progenitor Cells for  
483 Therapeutic Applications: Development of a GMP-Grade Manufacturing Method. *Frontiers in*  
484 *Physiology* 2018;9.

- 485 30. Burrello J, Burrello A, Stowasser M, et al.: The Primary Aldosteronism Surgical Outcome Score for  
486 the Prediction of Clinical Outcomes After Adrenalectomy for Unilateral Primary Aldosteronism.  
487 Ann Surg 2019.
- 488 31. Meyer LS, Wang X, Susnik E, et al.: Immunohistopathology and Steroid Profiles Associated With  
489 Biochemical Outcomes After Adrenalectomy for Unilateral Primary Aldosteronism. Hypertension  
490 2018;72:650-7.
- 491 32. Scardoni G, Tosadori G, Pratap S, Spoto F, Laudanna C: Finding the shortest path with PesCa: a  
492 tool for network reconstruction. F1000Res 2015;4:484.
- 493 33. Vella D, Zoppis I, Mauri G, Mauri P, Di Silvestre D: From protein-protein interactions to protein  
494 co-expression networks: a new perspective to evaluate large-scale proteomic data. EURASIP J  
495 Bioinform Syst Biol 2017;2017:6.
- 496 34. Puddu P, Puddu GM, Cravero E, Muscari S, Muscari A: The involvement of circulating  
497 microparticles in inflammation, coagulation and cardiovascular diseases. Can J Cardiol  
498 2010;26:140-5.
- 499 35. Kennel PJ, Saha A, Maldonado DA, et al.: Serum exosomal protein profiling for the non-invasive  
500 detection of cardiac allograft rejection. J Heart Lung Transplant 2018;37:409-17.
- 501 36. Habbertheuer A, Korutla L, Rostami S, et al.: Donor tissue-specific exosome profiling enables  
502 noninvasive monitoring of acute rejection in mouse allogeneic heart transplantation. J Thorac  
503 Cardiovasc Surg 2018;155:2479-89.
- 504 37. Vallabhajosyula P, Korutla L, Habbertheuer A, et al.: Tissue-specific exosome biomarkers for  
505 noninvasively monitoring immunologic rejection of transplanted tissue. J Clin Invest  
506 2017;127:1375-91.



- 507 38. Sukma Dewi I, Celik S, Karlsson A, et al.: Exosomal miR-142-3p is increased during cardiac  
508 allograft rejection and augments vascular permeability through down-regulation of endothelial  
509 RAB11FIP2 expression. *Cardiovasc Res* 2017;113:440-52.
- 510 39. Choi MY, Widhopf GF, 2nd, Wu CC, et al.: Pre-clinical Specificity and Safety of UC-961, a First-  
511 In-Class Monoclonal Antibody Targeting ROR1. *Clin Lymphoma Myeloma Leuk* 2015;15  
512 Suppl:S167-9.
- 513 40. Saleh RR, Antras JF, Peinado P, et al.: Prognostic value of receptor tyrosine kinase-like orphan  
514 receptor (ROR) family in cancer: A meta-analysis. *Cancer Treat Rev* 2019;77:11-9.
- 515 41. Burrello J, Monticone S, Gai C, Gomez Y, Kholia S, Camussi G: Stem Cell-Derived Extracellular  
516 Vesicles and Immune-Modulation. *Front Cell Dev Biol* 2016;4:83.
- 517 42. Margolis L, Sadovsky Y: The biology of extracellular vesicles: The known unknowns. *PLoS Biol*  
518 2019;17:e3000363.
- 519 43. Segura E, Amigorena S, They C: Mature dendritic cells secrete exosomes with strong ability to  
520 induce antigen-specific effector immune responses. *Blood Cells Mol Dis* 2005;35:89-93.
- 521 44. Ameyar M, Wisniewska M, Weitzman JB: A role for AP-1 in apoptosis: the case for and against.  
522 *Biochimie* 2003;85:747-52.
- 523 45. Holschermann H, Stadlbauer TH, Wagner AH, et al.: STAT-1 and AP-1 decoy oligonucleotide  
524 therapy delays acute rejection and prolongs cardiac allograft survival. *Cardiovasc Res* 2006;71:527-  
525 36.
- 526 46. Loupy A, Duong Van Huyen JP, Hidalgo L, et al.: Gene Expression Profiling for the Identification  
527 and Classification of Antibody-Mediated Heart Rejection. *Circulation* 2017;135:917-35.
- 528 47. Khan D, Ansar Ahmed S: The Immune System Is a Natural Target for Estrogen Action: Opposing  
529 Effects of Estrogen in Two Prototypical Autoimmune Diseases. *Front Immunol* 2015;6:635.

- 530 48. Morgan AE, Dewey E, Mudd JO, et al.: The role of estrogen, immune function and aging in heart  
531 transplant outcomes. *Am J Surg* 2019;218:737-43.
- 532 49. Bouman A, Heineman MJ, Faas MM: Sex hormones and the immune response in humans. *Hum*  
533 *Reprod Update* 2005;11:411-23.
- 534 50. Ansar Ahmed S, Penhale WJ, Talal N: Sex hormones, immune responses, and autoimmune diseases.  
535 *Mechanisms of sex hormone action. Am J Pathol* 1985;121:531-51.
- 536

537 **TABLE LEGENDS**

538 *Table 1 –Characteristics of patients from the training cohort.* Sex, age at heart transplant (HT),  
539 endomyocardial biopsy (EMB) characteristics, cellular rejection score (RS) and HLA-I/II donor- specific  
540 and nonspecific antibodies (DSA) in patients from the training cohort, without rejection (R0; n=33), with  
541 cellular-mediated (ACR; n=11) or with antibody-mediated rejection (AMR; n=9). *P*-values of less than  
542 0.05 were considered significant (in bold).

543

544 **FIGURE LEGENDS**

545 *Figure 1 – EV characterization.* Characterization of circulating extracellular vesicles (EV) from patients  
546 of the training cohort with cellular-mediated rejection (ACR; orange; n=11), antibody-mediated rejection  
547 (AMR blue; n=9), compared to controls without graft rejection (rejection 0, R0; green; n=33). (A) Patient  
548 samples underwent serial centrifugation and then EV were characterized by nanoparticle tracking  
549 analysis (NTA) and standardized multiplex flow cytometry for the evaluation of 37 different EV surface  
550 antigens. (B) Western blot analysis of plasma and EV isolated by bead immuno-capture (n=4) for 2 EV  
551 markers (TSG101 and CD81) and a potential contaminant (Apolipoprotein, B48). (C) Median  
552 fluorescence intensity (MFI, %) of CD9, CD63, and CD81 by flow cytometric analysis. (D) Cumulative  
553 distribution plot combining EV concentration (n/mL; y axis) and diameter (nm; x axis). (E) Correlation  
554 between EV concentration and CD9-CD63-CD81 MFI. The regression line is depicted in red, with a 95%  
555 confidence interval. Data are expressed as median and interquartile range (panel C). *P* values < 0.05 were  
556 considered significant (\**P* < 0.05; \*\**P* < 0.01).

557

558 *Figure 2 – EV-surface markers.* Median fluorescence intensity (MFI, expressed as a percentage [%],  
559 after normalization with mean MFI of CD9, CD63, and CD81) for differentially expressed EV surface  
560 markers in patients with cellular-mediated rejection (ACR; orange; n=11), antibody-mediated rejection

561 (AMR; blue; n=9), or without graft rejection (rejection 0, R0; green; n=33). (A) EV surface markers were  
562 divided into three groups in which EV markers were significantly increased: in patients with ACR vs. R0  
563 (left), in patients with AMR vs. R0 (right), and both rejection groups vs. R0 (middle). Patients with ACR  
564 are represented in orange (n=11), AMR in blue (n=9), and the R0 group in green (n=33). Horizontal lines  
565 on the circles indicate significant increases compared to R0 ( $P < 0.05$ ). (B) Heat map representing EV  
566 surface marker expression in patients stratified for diagnosis (red, low fluorescence; green, high  
567 fluorescence)..

568

569 **Figure 3 – Diagnostic performances of EV surface markers.** Diagnostic performances of EV surface  
570 markers differentially expressed in patients without rejection (R0) compared to cellular-mediated  
571 rejection (ACR; n=44; panels A and C) and antibody-mediated rejection (AMR; n=42; panels B and D).  
572 The area under the curve (AUC), asymptotic difference compared to the referral line (dashed grey line),  
573 sensitivity, and specificity are reported for each marker.

574

575 **Figure 4 – Diagnostic Modelling.** Random forest (RF) model for the diagnosis of allograft rejection  
576 using MFI values for the 11 EV surface markers differentially expressed among patients with cellular-  
577 mediated rejection (ACR; orange; n=11), antibody-mediated rejection (AMR blue; n=9), compared to  
578 controls without graft rejection (rejection 0, R0; green; n=33). (A) Double level RF model. Level 1  
579 identifies patients with graft rejection, whereas Level 2 distinguishes between AMR and ACR. (B)  
580 Combined model discriminating between R0, ACR, and AMR in a single step. Representative  
581 classification trees and confusion matrix at training and internal validation of the model are reported for  
582 each model. The sole missing patient with rejection is highlighted in red.

583






584 *Figure 5 – External validation of random forest diagnostic models.* The random forest models (level  
585 1, level 2, and the combined model) were validated on an independent external cohort (n=37). (A) Heat  
586 map representing EV surface marker expression in patients from the external validation cohort (n=37):  
587 acute cellular rejection (ACR; orange; n=13), antibody-mediated rejection (AMR; blue; n=4), or without  
588 graft rejection (rejection 0, R0; green; n=20). (B, C, and D) Confusion matrix reporting accuracy, real,  
589 and predicted diagnosis, are reported for each model. Missed rejecting patients are underlined in red.



590

591 *Figure 6 – Simulated application of EV profiling in clinical practice.* The random forest model (level  
592 1) was applicated to the validation cohort (n=37) to select patients for endomyocardial biopsy (EMB)  
593 (A) Management of heart transplanted patients using EMB as gold standard; all patients are correctly  
594 managed (accuracy 100%; number of EMB = 37). (B) Flow chart integrating EV profiling in patient  
595 management; 34 of 37 patients would be correctly managed (accuracy 91.9%; number of EMB = 16 [-  
596 56.8%]); 3 patients (in red) were misclassified and would miss the possibility to performed EMB.

597

598





**A****B**

**A**

RB vs. ACR (n=44)	AUC (95% CI)	P-value	Sensitivity (%)	Specificity (%)
CD3	0.848 (0.736-0.961)	<b>0.001</b>	90.9	75.8
CD2	0.829 (0.704-0.955)	<b>0.001</b>	100.0	81.8
ROR1	0.771 (0.627-0.915)	<b>0.008</b>	90.9	66.7
SSEA-4	0.832 (0.711-0.952)	<b>0.001</b>	100.0	83.6
HLA-I	0.939 (0.869-1.000)	<b>0.000</b>	100.0	87.9
CD41b	0.815 (0.653-0.978)	<b>0.002</b>	90.9	60.6


**B**

RB vs. AMR (n=42)	AUC (95% CI)	P-value	Sensitivity (%)	Specificity (%)
CD19	0.795 (0.648-0.942)	<b>0.007</b>	88.9	78.8
HLA-II	0.788 (0.653-0.922)	<b>0.009</b>	100.0	69.7
CD25	0.727 (0.568-0.886)	<b>0.039</b>	88.9	75.8
ROR1	0.879 (0.776-0.981)	<b>0.001</b>	100.0	75.8
SSEA-4	0.820 (0.692-0.947)	<b>0.004</b>	100.0	60.6
HLA-I	0.872 (0.757-0.988)	<b>0.001</b>	88.9	75.8
CD41b	0.778 (0.619-0.937)	<b>0.011</b>	100.0	51.5
CD326	0.788 (0.597-0.979)	<b>0.009</b>	88.9	69.7
CD20	0.798 (0.651-0.945)	<b>0.007</b>	88.9	81.8

**C****D**




**A**




Level 1	DETECTED at TRAINING		INTERNAL VALIDATION		
	R0	Rejection	R0	Rejection	
REAL	R0	33	0	28	5
	Rejection	0	20	1	19
Accuracy		100.0%		88.7%	

Level 2	DETECTED at TRAINING		INTERNAL VALIDATION		
	ACR	AMR	ACR	AMR	
REAL	ACR	11	0	10	1
	AMR	1	8	2	7
Accuracy		85.0%		85.0%	

**B**



Combined	DETECTED at TRAINING			INTERNAL VALIDATION			
	R0	ACR	AMR	R0	ACR	AMR	
REAL	R0	33	0	0	27	0	6
	ACR	0	11	0	0	10	1
	AMR	0	0	9	1	1	7
Accuracy		100.0%			83.0%		



**B**

Level 1		DETECTED	
		R0	Rejection
REAL	R0	18	2
	Rejection	3	14
Accuracy		86.5%	

**C**

Level 2		DETECTED	
		ACR	AMR
REAL	ACR	10	1
	AMR	0 + 2 R0	3
Accuracy		81.3%	

**D**

Combined		DETECTED		
		R0	ACR	AMR
REAL	R0	17	2	1
	ACR	3	9	1
	AMR	1	0	3
Accuracy		78.4%		

